Subcutaneous · GLP-1 agonist
Taspoglutide
13 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
13
Active
0
Recruiting
0
Completed
12
Sites
840
Countries
49
Endpoints
50
Composite endpoints
5
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 2
2
Phase 3
10
Trials by status
Completed
12
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
22
Safety / tolerability / PK
13
Other (unclassified)
5
Cardiovascular outcomes
4
Weight & body composition
4
Renal / kidney
1
Cardiometabolic biomarkers
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
9
HbA1c <7.0% achievementGlycemic
2
Expanded / custom MACE compositeCV
2
Fasting glucose, changeGlycemic
2
HbA1c <6.5% achievementGlycemic
1
Discontinuation due to AESafety/PK
1
Plasma concentration (steady state)Safety/PK
1
TmaxSafety/PK
1
All-cause deathCV
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
13 of 13